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Purpose of review: 
Electronic cigarettes have quickly risen to be the leading alternative nicotine source to tobacco. E-
cigarette use is hard to research and regulate due to the novelty and rapid evolution of the devices 
and E-liquids. Epidemiological data on long-term usage is currently lacking, but in smaller cohort 
studies we are starting to understand the usage patterns and demographics of users, which differ 
depending on where the study takes place and the regulatory environment. This review describes 
the current knowledge of the effects of E-cigarettes on the pulmonary system and knowledge of 
their usage patterns worldwide. 
 
Recent Findings: 
E-cigarette use is continuing to rise in young adults in USA and Canada, but not in UK. This suggests 
that regulation is influencing uptake in young adults.  If E-cigarettes are to be considered as a harm 
minimisation smoking cessation product, use in young never smokers must be factored into the risk 
assessment. A recent surge in cases of lung injury associated with vaping in America has resulted in 




It is our opinion that E-cigarettes can no longer be defined as harmless. Further studies are needed 
to determine the risks for all populations as it is evident that a large proportion of E-cigarette users 
are never smokers, meaning they can’t only be considered from a harm reduction perspective. 
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The idea of an electronic nicotine delivery device as an alternative to tobacco was first conceived in 
1963, but the first patented design came to market in 2003 [1]. Hon Lik originally designed the 
‘cigalike’ devices as an alternative to combustible tobacco and their popularity has been rapidly 
increasing since their introduction to America and Europe in 2007 [2]. The devices have evolved to 
more advanced customisable products, but a shift towards Pod style devices in recent years suggests 
discretion and convenience is preferred by users.  A good analogy to the different types of E-
cigarette devices is home coffee machines.  Some people prefer to roast, grind and brew their own 
coffee, whilst others opt for the convenience of prepacked coffee pods. The regulation surrounding 
E-cigarettes varies significantly throughout the world, although the development of devices and E-
liquids by hundreds of different international manufacturers has left an insurmountable task for 
regulators to tackle [3]. It seems that it is universally agreed that they shouldn’t be sold to minors, 
but beyond that opinions differ drastically on the harm versus benefit of E-cigarettes in different 
countries. In the United Kingdom a pro-E-cigarette position has been taken by Public health England, 
starting with the endorsement of Nutt et al. paper [4] proposing that E-cigarettes are 95% more 
healthy than tobacco cigarettes . This paper has been criticised for making conclusions without 
evidence to support their claims.  
 
E-cigarette uptake internationally 
In the USA and Canada a lack of regulation has contributed to an epidemic of E-cigarette use in 
young people. Recent data shows that E-cigarette use has significantly increased in young adults 
aged 16 to 19 between 2017 and 2018 [5]. E-cigarette use of 15 or more days in the last 30 days 
increased from 3.0% to 5.2% in USA and 2.1% to 3.6% in Canada. They also looked at changes in a 
cohort of 16 to 19 year olds from the UK, but no significant changes in prevalence of E-cigarette use 
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were found. The United Kingdom was quicker to act on regulating E-cigarettes and USA waited on a 
congressional hearing about increasing prevalence of youth E-cigarette use, where it was revealed 
that Juul Labs was offering financial incentives to talk to students about the safety of e-cigarettes 
[6]. Australia is currently much further behind in the regulation of E-cigarettes, with regulation only 
allowing the sale of non-nicotine containing E-liquids in as nicotine is a registered poison with the 
Therapeutic Goods Administration. 
Given the vast differences in international regulation of e-cigarettes it is important to evaluate 
recent evidence as to their effectiveness as a smoking cessation tool. A recent study by Hajek et al 
[7] compared the smoking cessation success of two cohorts, with one using nicotine replacement 
therapy (NRT) under the current therapeutic guidelines and the other using e-cigarettes as a 
replacement. They found that E-cigarettes were more effective as a cessation aid than NRT (18% vs 
9.9%). They also found that 80% of the E-cigarette cohort was still using their cessation product at a 
52 week follow up, suggesting that they hadn’t beaten their nicotine dependency. Conversely, a 
study by Gomajee et al [8] found that E-cigarette use in former smokers is associated with smoking 
relapse suggesting that E-cigarettes efficacy as a cessation aid could be more complicated than 
looking at short-term quit rates. 
 
E-cigarettes versus Tobacco 
The ongoing debate on whether E-cigarettes are more or less harmful than traditional tobacco 
cigarettes is delaying progress on regulation and distracting from the other major public health 
questions, particularly understanding the long-term population effects of E-cigarette use. It is clear 
that a lack of regulation is resulting in rapid uptake in younger non and never smokers, which may 
result in a rise in smoking rates among these populations [9, 10]. One of the big unanswered 
questions is will the potential harm minimisation from E-cigarette use in current smokers outweigh 
the rate of smoking relapse and uptake of smoking by never smokers? The National Academies of 
5 
 
Science, Engineering, and Medicine (NASEM) released a report in 2018 concluding that E-cigarette 
use results in reduced toxins, suggesting potential harm minimization [11].  
Furthermore, the question on whether E-cigarettes are harmful as a stand-alone product, without 
comparison to cigarettes is still being debated. In human clinical trials and in real life pragmatic 
studies the different combinations of machine, machine operating parameters, liquids, and usage 
time initially led to a lot of confusion.  In vivo and in vitro models have also been complicated by the 
lack of standard models, and the potential for models to be developed by those with commercial 
interests is worrying.   However, even with this turbidity, it is hard to ignore the clear majority of 
studies concluding that E-cigarettes are cytotoxic, pro-inflammatory, genotoxic and effect 
respiratory function of users after a single session.  
Higham et al [12] exposed Calu-3 cells and primary human bronchial epithelial cells in air liquid 
interface (ALI) culture to E-cigarette vapour extract resulting in an increase in proinflammatory 
cytokines IL-6 and CXCL8. The E-cigarette vapour extract was also cytotoxic to HBEC’s. A similar study 
using Beas-2Bs epithelial cell line in ALI found that E-cigarette exposure was not cytotoxic, and 
relatively inert when looking at inflammatory mediator production [13]. Of the 10 inflammatory 
mediators measured only IL-6 was upregulated. Contradictory studies are regularly found due to the 
lack of a standardised E-cigarette exposure model. The study by Anthérieu et al outlines in their 
methods that they bubble a defined amount of vapour, 16 x 3s puffs through cell culture media, but 
Higham et al state their dose as an OD value. Anthérieu et al also received funding for their study 
from Innova, a French E-cigarette company, which should be considered as a conflict of interest. 
Without standard exposure times, volumes of E-vapour, clarity on the devices and E-liquids used we 
move further away from an answer on the health effects of using E-cigarettes. Regular publication of 
unreproducible data further adds to the confusion and delays action by regulatory bodies.  
 
Immunological impact of E-cigarettes 
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Although the examples above point out some flaws in current E-cigarette research, it is evident that 
E-cigarettes have clear detrimental immunological effects in humans and on cells of the respiratory 
tract, cardiovascular system and immune system. Lugg et al [14] exposed primary alveolar 
macrophages (AM) to E-cigarette condensate finding upregulation of IL-6, TNFα, CXCL8, MCP-1 and 
MMP-1. They also found that both nicotine and nicotine free vapour condensates were pro-
apoptotic. Furthermore, addition of N-Acetyl Cystine (NAC) ameliorated the apoptosis suggesting 
ROS were responsible for the cytotoxicity. Ween et al [15] had similar findings in THP-1 macrophage 
cell line, with increased inflammatory markers after E-cigarette exposure and reduced phagocytotic 
ability. Post stimulation with E-cigarette vapour there was a reduction in expression of phagocytic 
surface receptors SR-A1 and TLR-2. Macrophages play a pivotal role in maintaining homeostasis 
within the lung, phagocytosing invading pathogens and apoptotic/necrotic host cells. The loss of 
macrophage function could result in increased infection and ineffective turnover and recycling of 
dead cells. It has also been shown that macrophages from e-cigarette exposed mice had significantly 
reduced ability to phagocytose bacteria than the macrophages of control mice [16], confirming that 
macrophage function is effected in the lung and in culture. This study also looked at viral infection in 
mice after E-cigarette exposure, with a significant decrease in viral clearance and an increase in 
morbidity and mortality. Furthermore, a study exposing mice to a range of Flavoured E-cigarettes 
both with and without nicotine looked at the effects on features of house dust mite-induced allergic 
[17]. All nicotine containing E-cigarettes suppressed airway inflammation but did not alter airway 
hyperresponsiveness or airway remodelling. Compared to room air, nicotine-free cinnacide 
flavoured E-cigarette exposure resulted in reduced total leukocytes and eosinophils, with an 
increase in airway hyperresponsiveness. Banana pudding E-cigarette exposure resulted in increased 
soluble lung collagen. These findings suggest that different E-liquid flavours may have a negative 




Higham et al [18] exposed primary human neutrophils to E-cigarette vapour to determine activation 
and inflammatory response. There was an increase in activation markers CD11b and CD66b after E-
cigarette exposure and increased secretion of MMP-9, Neutrophil Elastase and CXCL-8. These 
findings suggest that E-cigarette use would result in an increase in neutrophilic activation and 
recruitment. Dysregulated neutrophilic inflammation contributes to pathology in Chronic 
Obstructive Pulmonary Disease through increased matrix metalloproteinase (MMP) activity 
suggesting a plausible mechanistic link between e-cigarette use and long-term respiratory disease . 
Clapp et al [19] also found altered neutrophil function and cytokine production after E-cigarette 
exposure. There was a decrease in phagocytosis from several different E-liquid extract exposures, 
further supporting the increased risk of infection due to e-cigarette use. The impact of increased 
MMP activity could be explained in Ghosh et al study, where E-cigarette users, smokers and non-
smokers received bronchial brushings to determine any changes in bronchial epithelial protein 
expression [20]. They found 113 uniquely altered proteins in E-cigarette users, and 78 proteins 
altered in both E-cigarette users and smokers. Furthermore, E-cigarette users and smokers both 
experienced frequent coughing, poor tolerance for the bronchoscope and had erythematous airway 
mucosa, with more irritability and redness in the e-cigarette users.  
 
Pulmonary and Cardiovascular complications from E-cigarette use 
Mucocilliary dysfunction after E-cigarette exposure has been found in an ex vivo model of 
mucocilliary transport using Bullfrog Pallets [21]. There were similar findings in HBEC’s and in vivo in 
a Sheep model [22]. Exposure to E-cigarette vapor reduced airway surface liquid hydration and 
increased mucus viscosity of HBECs in a nicotine-dependent manner. In both ex vivo and in vivo 
models E-cigarettes caused a reduction in tracheal mucous velocity (TMV). Cystic fibrosis 
transmembrane conductance regulator ion channel (CTFR) is also functionally altered after E-
cigarette vapour exposure [23]. CTFR dysfunction is a proposed mechanism for mucus obstruction in 
chronic bronchitis and is also found in Cystic Fibrosis. These studies suggest that E-cigarettes could 
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worsen symptoms and lung function for patients with lung diseases. There is currently no data on E-
cigarette use in cystic fibrosis patients, but there has been a steady increase in use in patients with 
COPD or long-term smokers at risk of developing COPD [24]. The use of E-cigarettes in the at risk and 
COPD groups was associated with worse pulmonary related health outcomes such as increased 
prevalence of chronic bronchitis or a greater likelihood of COPD disease progression. Primary human 
airway smooth muscle cells from COPD patients had increased production of pro-inflammatory 
mediators compared to cells from healthy patients[25]. E-cigarettes could exacerbate the chronic 
inflammatory environment in the lungs of COPD patients and shouldn’t be considered as a safe 
option for smoking cessation. A maternal E-cigarette exposure model using mice measured 
inflammation and DNA methylation in mothers exposed to E-cigarettes and their offspring who were 
exposed second-hand when feeding from the mother [26]. Mothers had increased TNFα, IL-6, IL1β 
measured after weening of pups, whereas offspring had increased TNFα and suppressed IL1β. They 
also found a global increase in methylation. Although there is current paucity of literature on 
intergenerational impacts of maternal e-cigarette use [27], in utero nicotine exposure has been 
shown to cause epigenetic aberrations and induce asthmatic pathology in offspring that persisted 
into the third generation [28]. This is most pertinent as smoking women have been shown to swap 
to e-cigarettes during pregnancy, believing it is a healthier alternative to smoking [29], therein 
propagating not yet identified health risks to further generations. 
E-cigarettes have been shown to effect respiratory mechanical function of young healthy male study 
participants [30]. A cohort of 30 E-cigarette users performed a range of lung function tests and their 
results were compared against 30 healthy non-E-cigarette users. They found a pattern indicative of 
peripheral airway obstruction or small airways dysfunction, confirming that E-cigarette use had 
acute effects on lung function. Conversely another study [31] found that E-cigarette use had no 
effect on lung function in both asthma patients and healthy controls. In this study participants 
completed a 1 hour vaping session of a high-grade and contaminant-free mixture of propylene glycol 
and glycerol, with no flavourings or nicotine. This study isn’t representative of normal E-cigarette 
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use should be repeated to include an E-liquid containing nicotine to show any harm minimisation 
potential if used as a smoking cessation device.  
There has been a recent surge in hospital admissions in the USA due to lung injury associated with e-
cigarette use. This has resulted in the definition of Vaping Associated Pulmonary Injury (VAPI) [32] 
which the USA Center for Disease Control and Prevention defines as e-cigarette use in the 90 days 
prior to symptoms, presence of pulmonary infiltrates on chest computed tomography imaging and 
no evidence of alternative diagnoses such as pulmonary infection or non-pulmonary disease. Four 
chest imaging patterns associated with VAPI have been identified; acute eosinophilic pneumonia, 
diffuse alveolar damage, organizing pneumonia, and lipoid pneumonia [33]. VAPI has been 
suggested to be characterised by lipid-laden alveolar macrophages , consistent with the recent 
finding that mice exposed to e-cigarettes had accumulation of lipids within alveolar macrophages 
and epithelial cells, altered surfactant homeostasis and impaired viral immunity . However, another 
study did not show lipid accumulation in macrophages in those with VAPI (ref). No common 
compound/ingredient has been identified, although the majority of patients reported use of 
Tetrahydrocannabinol or Cannabidiol (Layden NEJM 2019). However, given the large number of 
users of e-cigarette liquids containing cannabis, the relatively small number of cases, and the lack of 
regulation of e-cigarette liquid manufacturing in USA, there remains uncertainty as to the underlying 
cause of VAPI.  
 
The health effects of E-cigarettes extend beyond the respiratory system, with growing concerns for 
cardiovascular health of E-cigarette users. The Health eHeart study [34] looked at how E-cigarette, 
cigarette and dual use influenced cardiopulmonary symptoms in patients. E-cigarette only use was 
associated with higher occurrence of chest pain, palpitations, coronary heart disease and 
arrhythmia. This study only has a low proportion of E-cigarette only users (1.4%) and didn’t identify 
whether any of these reported cardiovascular symptoms were from pre-existing conditions. Osei et 
al pooled data from the behavioural risk factor surveillance system, finding that E-cigarette users 
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and concurrent smokers who use E-cigarettes were at greater risk of cardiovascular disease [35]. 
Further studies need to be done to identify how E-cigarettes affect the cardiovascular health of 
users vs non users. Lee et al [36] found that exposure to E-cigarette liquid caused endothelial cell 
dysfunction which is a precursor to myocardial infarction and other cardiovascular diseases. The 
exposure to un-vapourised E-liquid is not a physiologically relevant model as endothelial cells would 
only come into contact with the E-liquid in this form if it was ingested 
 
E-liquid flavours 
A regular focus point of in vitro studies is how flavour additives effect immunological response and 
cytotoxicity. It was last estimated in 2014 that there were more than 7500 different E-liquids 
available for purchase, this number is likely much larger today [37]. It is clear that the constituents of 
E-liquids affect the response from cells after exposure, including the flavour molecules in these 
liquids. Current regulation does not require manufacturers to test how harmful flavour molecules 
are on respiratory cells, or whether they are safe to inhale after vaporisation at high temperature. 
Krüsemann et al [37] proposed a new classification system for E-cigarette flavours with 13 main 
categories and 90 subcategories. They generated the categories from current E-liquid flavours 
names found in a literature search grouping them on common linking flavour groups they belonged 
to. A universal categorical system for E-cigarette flavours is a starting point for E-cigarette research 
with ingredients already known to have harmful effects, such as diacetyl [38], being banned from 
use. but much more needs to be done by the scientific community to set appropriate parameters on 
research expectations. A lack of universal in vitro and in vivo exposure models makes it difficult to 
compare two different studies. There is also very little transparency in the methodology used by 
researchers, further complicating the comparison of research to date.  
One of the biggest dangers with E-cigarette use is its inherent novelty. Not only does it heighten its 
appeal, and make it hard to research and regulate; but also means there is a current dearth of 
epidemiological data on long-term usage consequences. Identifying any possible health risks is made 
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more arduous by the comparison to cigarettes, which draws scientists and regulators into primarily 
assessing cigarette smoked induced changes and pathology as outcomes in studies.  However, the 
basic constituents of E-cigarettes and cigarettes are radically different, and therefore E-cigarettes 
are likely to cause novel diseases.  For example, inhalation of silicates in the form of asbestos causes 
radically different diseases to the inhalation of quartz [39].  Thereby we advocate for it to be of 
utmost importance that the scientific and medical communities are on high alert for novel 
pathological manifestations attributable to long-term E-cigarette use.  
 
Conclusion: 
It is our opinion that E-cigarettes can no longer be defined as harmless. Furthermore, the toxicity 
profile of e-cigarettes should not only be compared to tobacco cigarettes but considered in their 
own light i.e. as compared to never users. If e-cigarettes were prescription only smoking quit aids 
their utility and relative risk in the community would be very different to their use as recreational 
drug (nicotine) delivery system.  When evaluating risks, differing points of view has led authors into 
presenting the data in ways to support their respective argument. We recommend further debate 
and studies to thoroughly discern the risks for all populations. In particular, studies focused on at-
risk populations, such as teenagers, pregnant women, children, and people with pre-existing medical 
conditions need to be defined separately from those investigating risks associated with E-cigarette 
use as a quit aid or tobacco replacement product.   
 
Key Themes: 
• E-cigarettes can no longer be considered harmless, and should be considered in their own 
light without comparison to tobacco cigarettes. 
• There is evidence for immunological, respiratory and cardiovascular complications from 
short or long-term E-cigarette use. 
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• Regulations on E-cigarettes have an impact on the demographics that use them, hence 
further restrictions are needed to protect non-smokers and at risk populations. 
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